BR112013000867A2 - composto de purina seletivos para delta p110 de pi3k e métodos de uso. - Google Patents

composto de purina seletivos para delta p110 de pi3k e métodos de uso.

Info

Publication number
BR112013000867A2
BR112013000867A2 BR112013000867A BR112013000867A BR112013000867A2 BR 112013000867 A2 BR112013000867 A2 BR 112013000867A2 BR 112013000867 A BR112013000867 A BR 112013000867A BR 112013000867 A BR112013000867 A BR 112013000867A BR 112013000867 A2 BR112013000867 A2 BR 112013000867A2
Authority
BR
Brazil
Prior art keywords
delta
pi3k
methods
purine compound
compounds
Prior art date
Application number
BR112013000867A
Other languages
English (en)
Inventor
Brian Safina
Daniel P Sutherlin
Jun Li
Zachary Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013000867A2 publication Critical patent/BR112013000867A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composto de purina seletivos para delta p110 de pi3k e métodos de uso. a invenção provê compostos que tem a fórmula geral: e estereoisômeros, tautômeros ou sai aceitos farmaceuticamente desses, em que r^1^,r^2^,r^3^,r^4^ e n são definidos aqui, composições incluindo os compostos e método de utilizar os compostos para tratar uma doença ou distúrbio mediado pelo isoforma delta de p110 de quinase pi3 selecionado de distúrbios imunológicos, câncer, doenças cardiovasculares, infecção viral, inflamação,distúrbios de funções de metabolismo/endócrinas e distúrbios neurológicos.
BR112013000867A 2010-07-14 2011-07-13 composto de purina seletivos para delta p110 de pi3k e métodos de uso. BR112013000867A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36432410P 2010-07-14 2010-07-14
PCT/EP2011/061930 WO2012007493A1 (en) 2010-07-14 2011-07-13 Purine compounds selective for ρi3κ p110 delta, and methods of use

Publications (1)

Publication Number Publication Date
BR112013000867A2 true BR112013000867A2 (pt) 2016-05-17

Family

ID=44532789

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000867A BR112013000867A2 (pt) 2010-07-14 2011-07-13 composto de purina seletivos para delta p110 de pi3k e métodos de uso.

Country Status (11)

Country Link
US (1) US8293736B2 (pt)
EP (1) EP2593455B1 (pt)
JP (1) JP5555378B2 (pt)
KR (1) KR101531117B1 (pt)
CN (1) CN103003279B (pt)
BR (1) BR112013000867A2 (pt)
CA (1) CA2802808A1 (pt)
ES (1) ES2536780T3 (pt)
MX (1) MX2013000389A (pt)
RU (1) RU2013104038A (pt)
WO (1) WO2012007493A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック, インコーポレイテッド プリンpi3k阻害剤化合物および使用方法
CN102711766B (zh) * 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
CA2820078C (en) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
US9949979B2 (en) 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
RU2663999C2 (ru) 2013-10-16 2018-08-14 Шанхай Инли Фармасьютикал Ко., Лтд Конденсированное гетероциклическое соединение, способ его получения, его фармацевтическая композиция и применения
WO2015188369A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2016064957A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
CA2980517C (en) 2015-03-30 2020-02-25 Daiichi Sankyo Company, Limited 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
GB201514751D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
TW201817731A (zh) * 2016-09-29 2018-05-16 日商第一三共股份有限公司 [2-(1-甲基-1h-吡唑-4-基)-6-( 啉-4-基)-9h-嘌呤-8-基][4-( 啉-4-基)哌啶-1-基]甲酮及其製藥上容許鹽之結晶
KR102399639B1 (ko) 2016-12-02 2022-05-18 다이이찌 산쿄 가부시키가이샤 신규 엔도-β-N-아세틸글루코사미니다아제
JP7358890B2 (ja) 2019-10-01 2023-10-11 富士フイルムビジネスイノベーション株式会社 物体質感計測装置

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016378A (en) 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
DE60144322D1 (de) 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
AU2002323475B2 (en) 2001-09-13 2006-09-28 Synta Pharmaceuticals Corp 2-aroylimidazole compounds for treating cancer
EP1578722A4 (en) 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
JP4768265B2 (ja) * 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
CA2527079A1 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
BRPI0617165B1 (pt) 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
AU2007243457B2 (en) 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
AR060632A1 (es) 2006-04-26 2008-07-02 Genentech Inc Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso
AR060631A1 (es) * 2006-04-26 2008-07-02 Piramed Ltd Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
CN101675053B (zh) 2006-12-07 2014-03-12 健泰科生物技术公司 磷酸肌醇3-激酶抑制剂化合物及使用方法
JP5284977B2 (ja) 2006-12-07 2013-09-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2008116911A1 (en) 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
CA2692050A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
JP5736171B2 (ja) * 2007-09-24 2015-06-17 ジェネンテック, インコーポレイテッド チアゾロピリミジンpi3k阻害剤化合物および使用方法
EP2209785A1 (en) * 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
WO2009053716A1 (en) * 2007-10-26 2009-04-30 F.Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
JP2011521968A (ja) 2008-05-30 2011-07-28 ジェネンテック, インコーポレイテッド プリンpi3k阻害剤化合物および使用方法
AU2009269087A1 (en) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc PI3K isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
SG174527A1 (en) * 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CA2761445A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
AR080945A1 (es) * 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer

Also Published As

Publication number Publication date
KR20130038921A (ko) 2013-04-18
WO2012007493A1 (en) 2012-01-19
EP2593455A1 (en) 2013-05-22
CA2802808A1 (en) 2012-01-19
US8293736B2 (en) 2012-10-23
CN103003279B (zh) 2015-09-23
EP2593455B1 (en) 2015-03-18
JP2013531022A (ja) 2013-08-01
CN103003279A (zh) 2013-03-27
MX2013000389A (es) 2013-03-08
JP5555378B2 (ja) 2014-07-23
US20120015931A1 (en) 2012-01-19
ES2536780T3 (es) 2015-05-28
KR101531117B1 (ko) 2015-06-23
RU2013104038A (ru) 2014-08-20

Similar Documents

Publication Publication Date Title
BR112013000867A2 (pt) composto de purina seletivos para delta p110 de pi3k e métodos de uso.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
MX2009010881A (es) Compuestos farmaceuticos.
IL201365A0 (en) Pyrimidine derivatives as inhibitors of phosphatidylinositol - 3 kinase
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NO20084931L (no) Farmasoytiske sammensetninger
MX2009002171A (es) Derivados de triazol como inhibidores de cinasas.
MX346336B (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
EA201590624A1 (ru) Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения
MX2011012520A (es) Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
WO2009132202A3 (en) Macrocyclic compounds and their use as kinase inhibitors
MX2010004705A (es) Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
EA201290305A1 (ru) Производные трициклического пиразоламина
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2008060621A3 (en) Aminopyrrolidines as chemokine receptor antagonists
MX2010005700A (es) Amino triazoles como inhibidores pi3k.
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
WO2013038429A3 (en) Novel sglt inhibitors
WO2012101654A3 (en) Novel triazine compounds
NO20085257L (no) Purinonderivater som HM74a-agonister
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
MX2009009154A (es) Derivados de espiro-pirano-pirazol.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]